Navigation Links
AFFiRiS AG - Encouraging Results From Phase I Studies of two Alzheimer's Candidate Vaccines Trigger a EUR 10 Million Milestone Payment
Date:10/20/2009

VIENNA, Austria, October 20 /PRNewswire/ -- AFFiRiS AG today announced that the primary endpoints have been met for the Phase I clinical studies of its two Alzheimer's vaccines AD01 and AD02, which demonstrated favourable safety and tolerability profiles. These results trigger a 10 million EUR milestone payment from licensee GlaxoSmithKline Biologicals.

All 48 patients treated in these studies were given four vaccinations which were well tolerated and no serious side effects associated with the vaccine candidates were observed.

The results demonstrate the potential value of the AFFITOME(R) technology, which forms the platform for both of these vaccines and could result in a generation of highly specific vaccines. While analysing the clinical outcome in detail the company, together with GSK Biologicals is progressing to the next development stage. AFFiRiS AG is also using AFFITOME(R) technology to develop vaccines for Parkinson's disease, atherosclerosis and four other indications.

Affinity to Success

Commenting on the results, AFFiRiS' CEO, Dr. Walter Schmidt, said: "This initial demonstration of safety and tolerability is an outstanding milestone in our joint efforts with GSK Biologicals to develop a therapeutic Alzheimer's vaccination. However, the results also highlight the potential capability of our AFFITOME(R) technology, which forms the basis for the two vaccine candidates. This technology is also the platform for our six other vaccine programmes, including Parkinson's and atherosclerosis currently under development. The results not only represent an important milestone in the development of our Alzheimer's vaccination but also confirm our basic strategy. We will be investing all of this milestone payment in our research and development projects."

In October 2008 AFFiRiS concluded a licensing agreement with GSK Biologicals on jointly developing the Alzheimer's vaccin
'/>"/>

SOURCE AFFiRis AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. AFFiRiS Begins Development of a Parkinsons Vaccine
2. AFFiRiS: Milestone Reached in Clinical Trial of Alzheimers Vaccine
3. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
4. Encouraging First Data on New Targeted Treatment for Patients With Melanoma - the Deadliest Form of Skin Cancer
5. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
6. Encouraging Gene Therapy Results in Genetic Form of Blindness
7. Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO
8. Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa
9. PTC Therapeutics Presents Encouraging Phase 1 Results of its Novel VEGF Inhibitor, PTC299, at 30th Annual San Antonio Breast Cancer Symposium
10. Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
11. New UNAIDS Report Offers Encouraging News, But Most HIV-Positive Mothers Still Not Getting the Care & Treatment They Need
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/6x789c/new_eu ) has announced ... (London, UK - November 16-17, 2015)" conference to ... modules concerning Pharmacovigilance are a major departure in terms ... Europe . The intention of the course is ... how they overlap and fit together and what Companies ...
(Date:9/2/2015)... Research and Markets ... Jain PharmaBiotech,s new report "Therapeutic Drug Monitoring ... offering. This report deals with therapeutic ... improving patient care by monitoring drug levels in ... drugs for improving outcome. TDM is viewed as ...
(Date:9/2/2015)... 2, 2015  ArmaGen, Inc., a privately held ... treat severe neurological disorders, announced today that the ... Phase 1/2a clinical trial of AGT-181 in patients ... AGT-181 is an investigational enzyme replacement ... The most severe form of MPS I, Hurler ...
Breaking Medicine Technology:Global Therapeutic Drug Monitoring Technologies, Markets, and Companies Report 2015 - Updated 2015 Analysis with Forecasts to 2024 2ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 2ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 3ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 4
... 16, 2011 White Smile Global Inc. (OTCBB: WSML) ... update on the Company. Upon appointment of ... Giniger DMD, PhD, MsD, FICD, the Company has recently ... have been purchased in full from the world renowned Bio-Chemist. ...
... 2011 Healthcare Quality Catalyst Corp. ( www.hqcatalyst.com ), ... series of important events since September 2011 to continue ... SEQUOIA CAPITAL INVESTMENT ... announced the selection of Sequoia Capital as its investment ...
Cached Medicine Technology:White Smile Global Inc. Corporate Update on the White Smile Premier™ "At-Home" LED Teeth Whitening System and the White Smile Tooth Gloss™, Including Clinical Study, Product Manufacturing, and Distribution 2White Smile Global Inc. Corporate Update on the White Smile Premier™ "At-Home" LED Teeth Whitening System and the White Smile Tooth Gloss™, Including Clinical Study, Product Manufacturing, and Distribution 3Healthcare Quality Catalyst Partners With Sequoia, Adds Three Healthcare Veterans 2Healthcare Quality Catalyst Partners With Sequoia, Adds Three Healthcare Veterans 3Healthcare Quality Catalyst Partners With Sequoia, Adds Three Healthcare Veterans 4Healthcare Quality Catalyst Partners With Sequoia, Adds Three Healthcare Veterans 5
(Date:9/2/2015)... ... ... A recent survey by Consumer Reports ( http://bit.ly/1h67tL8 ) sheds light on ... consumers. It was reported that 33% are paying an average of $39 more out-of-pocket ... $100 compared to last year. Among the drugs that saw the highest increases were ...
(Date:9/2/2015)... ... September 02, 2015 , ... World ... Free Pocket Cop, a safety invention that protects people from crime and other ... billion," says Scott Cooper, CEO and Creative Director of World Patent Marketing. "The ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... SERVICE GROUP is internationally known as an industry leader specializing in surplus used ... world, selling more than 100,000 pieces of medical equipment every year. Erik Tivin, ...
(Date:9/2/2015)... ... September 02, 2015 , ... Ovarian cancer continues to ... woman’s risk of getting ovarian cancer in her lifetime is approximately 1 in 75. ... of ovarian cancer, and 14,000 will die. , There is no test to ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... to bring awareness to International Overdose Awareness Day. The goal is to provide ... the warning signs so that they may get help. , Lakeview ...
Breaking Medicine News(10 mins):Health News:Watertree Health President Responds to Consumer Reports Survey on Rising Prescription Drug Prices 2Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 2Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 3Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 4Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 5Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 6Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 7Health News:Over 1800 Lots of Surplus Used Medical Equipment 2Health News:Over 1800 Lots of Surplus Used Medical Equipment 3Health News:National Ovarian Cancer Coalition's DFW Chapter Features First Annual Teal Lights Display This Friday, September 4th, "National Wear Teal Day" 2Health News:National Ovarian Cancer Coalition's DFW Chapter Features First Annual Teal Lights Display This Friday, September 4th, "National Wear Teal Day" 3Health News:August 31 is International Overdose Awareness Day – Lakeview Health to Help Bring Awareness 2
... Alcohol Provides Parents Resources to Help Manage Teen ... Access to Alcohol in the ... Alcohol today challenged New York area parents to take a tough,topic ... a roundtable discussion featuring a panel of experts from the fields,of ...
... to a study using a dynamic in vitro gastrointestinal ... SHQ) ulcerative colitis drug LIALDA (mesalamine) demonstrated a delivery ... 5-aminosalicyclic acid (5-ASA), is released over a prolonged period ... site of inflammation in ulcerative colitis. In this in ...
... any more sensitive in detecting biological motion compared with ... of Vision, an online, free-access publication of the Association ... Eric Hiris of St. Mary,s College of Maryland, (St ... on the subject begin with statements to the effect ...
... employee assistance,division of Recovery Resources Inc., is offering ... of October in,recognition of national Drug-Free Work Week ... an effective drug free workplace program. The ... 2007" in an,effort to educate businesses about the ...
... - With Photo - Business Executives Encouraged to ... Stroke and Funds for the Stroke Association Tom ... Olympic gold medallist, today launched ,Siemens Stroke for Stroke,Week, ... to,highlight the positive benefits of regular exercise and to ...
... New benefit offered to 10,000 Medicare Choice PPO members at no additional ... ... YORK, Oct. 17 Effective January 1, 2008, Group,Health Incorporated (GHI) has ... call a toll-free number to speak with,their own independent Personal Health Advocate ...
Cached Medicine News:Health News:Parents Encouraged to Set an Example for Their Teens and Help Stop Underage Drinking 2Health News:Parents Encouraged to Set an Example for Their Teens and Help Stop Underage Drinking 3Health News:Parents Encouraged to Set an Example for Their Teens and Help Stop Underage Drinking 4Health News:Parents Encouraged to Set an Example for Their Teens and Help Stop Underage Drinking 5Health News:LIALDA demonstrates prolonged release of mesalamine in an in vitro study using a simulated colon 2Health News:LIALDA demonstrates prolonged release of mesalamine in an in vitro study using a simulated colon 3Health News:AssistNow Offers Area Employers Complimentary Needs Assessment in Recognition of National Drug-Free Work Week 2Health News:James Cracknell Launches Siemens Stroke for Stroke Week 2Health News:James Cracknell Launches Siemens Stroke for Stroke Week 3Health News:James Cracknell Launches Siemens Stroke for Stroke Week 4Health News:GHI to Provide Independent Personal Health Advocate for Medicare Members 2
The ImagingPlanet 80 mm Surgical Microscope Adapter. Superior optical quality and precise engineering make this 80 mm focal length adapter an excellent decision for use with your Zeiss surgical micro...
The ImagingPlanet 55 mm Surgical Microscope Adapter. Superior optical quality and precise engineering make this 55mm focal length adapter an excellent decision for use with your Zeiss surgical micro...
The ImagingPlanet 70 mm Surgical Microscope Adapter. Superior optical quality and precise engineering make this 70 mm focal length adapter an excellent decision for use with your Leica surgical micr...
... Archive Manage and ... ,Introducing Optronics DVMR- office, the ... designed for the physician's office ... a variety of high-resolution cameras ...
Medicine Products: